Arcturus Therapeutics Holdings Inc.
General ticker "ARCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $408.1M (TTM average)
Arcturus Therapeutics Holdings Inc. follows the US Stock Market performance with the rate: 19.0%.
Estimated limits based on current volatility of 3.6%: low 6.42$, high 6.89$
Factors to consider:
- Total employees count: 176 (-2.2%) as of 2024
- Top business risk factors: Clinical trial execution risks, Intellectual property risks, Government contract risks, Regulatory and compliance, Operational and conduct risks
- Current price 17.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.24$, 20.08$]
- 2025-12-31 to 2026-12-31 estimated range: [7.28$, 17.50$]
Financial Metrics affecting the ARCT estimates:
- Negative: with PPE of -5.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.67 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.15 > -0.66
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Shareholder equity ratio, % of 70.04 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ARCT quotes
Long-term ARCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $206.00MM | $157.75MM | $138.39MM |
| Operating Expenses | $193.82MM | $235.95MM | $234.06MM |
| Operating Income | $12.18MM | $-78.20MM | $-95.67MM |
| Non-Operating Income | $-1.53MM | $50.31MM | $14.72MM |
| Interest Expense | $0.00MM | $0.77MM | $0.00MM |
| R&D Expense | $147.75MM | $192.13MM | $195.16MM |
| Income(Loss) | $10.64MM | $-27.89MM | $-80.94MM |
| Taxes | $1.29MM | $1.83MM | $-0.00MM |
| Profit(Loss)* | $9.35MM | $-29.73MM | $-80.94MM |
| Stockholders Equity | $270.31MM | $278.51MM | $240.98MM |
| Assets | $450.39MM | $429.40MM | $344.07MM |
| Operating Cash Flow | $31.99MM | $-18.10MM | $-59.75MM |
| Capital expenditure | $7.73MM | $2.90MM | $0.65MM |
| Investing Cash Flow | $-7.73MM | $-2.90MM | $-0.65MM |
| Financing Cash Flow | $-2.86MM | $-24.09MM | $5.42MM |
| Earnings Per Share** | $0.35 | $-1.12 | $-3.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.